ABSTRACT: Neuro-infl ammation plays a pivotal role in numerous neurodegenerative disorders, such as Parkinson's disease (PD). Traditional anti-infl ammatory drugs have limited therapeutic use because of their narrow spectrum and severe side eff ects after long-term use. Morphinans are a class of compounds containing the basic morphine structure. Th e following review will describe novel neuroprotective eff ects of several morphinans in multiple infl ammatory disease models. Th e potential therapeutic utility and underlying mechanisms of morphinan neuroprotection are discussed.
I. INTRODUCTION
Morphinans, which are a series of compounds structurally similar to morphine, including naloxone and naltrexone, are neuroprotective in a variety of neuro degenerative disease animal models. However, the mechanism underlying their neuroprotective effects is not clear. Morphine has been used for the treatment of spinal cord injury (SCI), and its eff ect was believed to be mediated through opioid receptors.¹-⁴ However, opioid receptor antagonists, such as naloxone or naltrexone, have also been reported to be neuroprotective in the SCI and brain ischemia animal models.⁵,⁶ Th us, it is questionable whether morphine-and naloxone-induced neuroprotection are mediated through opioid receptors. Moreover, many publications also indicate that dextromethorphan (DM) exerts neuroprotective eff ects in various brain and SCI models.⁷,⁸ Th e neuroprotective eff ect of DM has been attributed to its N-methyl-d-aspartate (NMDA) receptor antagonist property.
We have been interested in elucidating the possibility that novel mechanisms, which are not mediated through either opioid or NMDA receptors, may be associated with morphinan-induced neuroprotection. In this review, we propose that anti-infl ammatory eff ects of morphinans may underlie their neuroprotective eff ects. We will fi rst briefl y review the current concept of receptor-mediated neuroprotection of morphinans and then focus on the anti-infl ammatory eff ect of morphinans as a potential major mechanism for neuroprotection.
II. ROLE OF NMDA RECEPTOR IN MEDIATING MORPHINAN-INDUCED NEUROPROTECTION II.A. DM Protects Neurons Against Cerebral Ischemia
Th e fi rst evidence for a neuroprotective action of DM was reported by Choi,⁹ who demonstrated that DM off ered protection for primary neurons exposed to the excitotoxin glutamate.⁹ Shortly thereafter, it was shown in several in vivo models of ischemic brain injury that treatment with DM could protect the brain against infarction and related pathophysiological and functional consequences of injury.⁷,¹⁰-¹³ More recently, several in vitro¹⁴,¹⁵ and in vivo studies¹⁶-¹⁸ have confi rmed the neuroprotective actions of DM and have off ered critical insights into its possible cellular mechanism of action. In particular, comprehensive studies undertaken with the rodent focal ischemia/reperfusion (I/R) injury model showed the potent actions of DM to decrease the volume of cerebral infarction and improve functional recovery as a postinjury therapy.¹⁸ Interestingly, novel analogs of DM have been described as antagonists of glutamate-induced excitotoxic calcium signals in neurons,¹⁴,¹⁸ and one such analog-namely, the (+)-3-amino-17-methylmorphinan derivative AHN649-is an eff ective and safe neuroprotective agent possessing a similar potency, but improved safety profi le, when compared to DM.¹⁸ Although the aforementioned reports indicated that the neuroprotective eff ect of DM on cerebral ischemia is attributable to its NMDA antagonist property; research in our laboratory showed strong evidence that the neuroprotective eff ect of DM against infl ammation-related neurodegeneration is mediated through its anti-infl ammatory eff ect (see Section VIII).
II.B. Neuroprotection of DM and its Metabolite on Spinal Cord Injury (SCI)
With the development of experimental SCI models and recent advances in SCI research, many therapeutic regimens, such as anti-infl ammatory drugs,¹⁹,²⁰ immunosuppressive drugs,²¹ and receptor blockers²⁰ have been studied in animals. An in vivo study showed that a chronic allodynia-like response to mechanical stimulation was observed in rats after severe spinal cord ischemia.⁸ Th is allodynia-like response was not relieved by most conventional analgesics used for treating chronic neuropathic pain.²² Hao and Xu²² found that systemic DM relieved the mechanical allodynia-like response in a dose-dependent fashion. Th ey also observed increased spontaneous motor activity in the absence of severe motor impairment at analgesic doses. It is well known that the analgesic eff ect of most NMDA antagonists is associated with severe side eff ects, with psychomimetic eff ects being the most common. However, DM is known for its safety record and can be used for treating the chronic pain associated with SCI.²² Glutamate is a potent and rapidly acting neurotoxin on cultured spinal neurons, supporting the involvement of excitotoxicity mediated through NMDA receptors in acute SCI.²² Regan and Choi²³ found that exposure of mixed spinal cord neuron-glia cultures to glutamate for 5 minutes produced widespread acute neuronal swelling followed by neurodegeneration over the next 24 hours. By 14-20 days, 80-90% of the neuronal population was destroyed by a 5-minute exposure to glutamate. Both acute neuronal swelling and late neurodegeneration were eff ectively blocked by dextrophan (DT), the metabolite of DM.
Th e spinal cord and the brain are particularly vulnerable to free radical oxidation following traumatic insults because of their high lipid content²⁴ and poor iron-binding capacity.²⁵ In traumatic SCI, the lesion results not only from the direct (primary) physical trauma but also from the indirect (secondary) injury, associated with ischemia, edema, increased excitatory amino acids (EAAs), and oxidative damage to the tissue from reactive oxygen species (ROS),¹⁹ which in turn contribute to lipid peroxidation.¹⁹,²⁰,²⁴,²⁶,²⁷ Th e levels of the lipid peroxidation products, including malonyldialdehyde (MDA), superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px), can be measured in monitoring the degree of lipid peroxidation. It has been found that DM and DT²⁸-³⁰ block Ca² + entry into neurons as a result of both NDMA-antagonist¹¹,²⁸,²⁹,³¹-³³ and voltage-gated Ca² + infl ux-inhibiting eff ects. Topsokal et al.²⁵ found that DM was rather eff ective against spinal cord trauma at 120 minutes, which might have stemmed from the high plasma concentrations of DM at 60-120 minutes, as reported previously.²⁹ Kato³¹ used DT to protect the spinal cord from ischemia.
II.C. Neuroprotective Effect of DM Through its Anticonvulsant Effect
Several studies revealed that DM has a signifi cant anticonvulsant eff ect.³⁴-³⁶ DM was found to reduce the seizures and mortality and decreased the cell loss in the CA1 and CA3 areas of the hippocampus in a dose-dependent manner. One interpretation for the neuroprotective eff ect of DM through its anticonvulsant eff ect is that it reduces the excitotoxicity exerted on the neurons by glutamate through the inhibition of NMDA receptors. DM has also been shown to attenuate kainic acid (KA)-induced increases in AP-1 binding activity and C-Jun/FRA expression in the hippocampus, collectively suggesting that DM is an eff ective antagonist of KA and a potent protectant for convulsants.³⁴ Recently, new derivatives of DM also showed a promising anticonvulsant eff ect.³⁷,³⁸ Kim et al.³⁸ investigated the eff ect of a series of synthesized DM analogs (that were modifi ed in positions 3 and 17 of the morphinan ring system) on maximal electroshock convulsions (MES) in mice. Th ey found that DM, DT, 3-allyloxy-17-methylmorphinan (CPK-5), and 3-cyclopropylmethoxy-17-methylmorphinan (CPK-6) had anticonvulsant eff ects against MES, while 3-methoxymorphinan (3-MM), and 3-hydroxymorphinan (3-HM) did not show any anticonvulsant eff ects. Th ey found that DM, DT, CPK-5, and CPK-6 were high-affi nity ligands to sigma 1 receptors, while they all had low affi nity to sigma 2 receptors. DT had relatively higher affi nity for the phencyclidine (PCP) sites than DM. By contrast, CPK-5 and CPK-6 had very low affi nities for PCP sites, suggesting that PCP sites are not required for their anticonvulsant actions. Th eir results suggest that the new morphinan analogs are promising anticonvulsants that are devoid of PCP-like behavioral side eff ects, and their anticonvulsant actions may be, in part, mediated via sigma 1 receptors.³⁶ Another study indicated that the anticonvulsant eff ects of the morphinans partially involve the l-type calcium channel and that DM is a more potent anticonvulsant than DT in both KA-and BAY K-8644-induced seizure models.³⁵ BAY K-8644 is an l-type Ca² + channel agonist of the dihydropyridine class, which is recognized as a potent convulsant agent that can also potentiate seizures induced by KA. Th e anticonvulsant eff ect of a low dose of DM was reversed by BAY K-8644 in this model. In contrast, BAY K-8644 did not signifi cantly aff ect an anticonvulsant eff ect from a higher dose of DM and DT. Furthermore, DM appeared more effi cacious than DT in attenuation of KA-and BAY K-8644-induced seizures by decreasing KA-induced AP-1 DNA-binding activity and fos-related antigen-immunoreactivity, as well as reducing neuronal loss in the hippocampus.
III. ROLE OF OPIOID RECEPTOR-MEDIATED MORPHINAN NEUROPROTECTION

III.A. Naloxone Protects Neurons Against Cerebral Ischemia
Koc et al.³⁹ studied the eff ect of naloxone on focal cerebral ischemia induced by middle cerebral artery occlusion with the transorbital approach in a rabbit model. Animals receiving naloxone treatment showed improvement in neurological outcome. In addition, naloxone signifi cantly reduced the infarct size and edema compared to controls.⁴⁰ It was suggested that the attenuation of the disturbance of cellular functions following cerebral I/R via restoration of mitochondrial activities or energy metabolism is the mechanism of the neuroprotective eff ect of naloxone. Chen et al. ⁴¹ found that both pretreatment and post-treatment with naloxone by intracerebroventricular infusion significantly reduced cortical infarct volumes. Pretreatment with naloxone reduced ischemia-induced suppression of the extracellular pyruvate level and enhancement of the lactate/pyruvate ratio, as well as cerebral I/Rinduced increases of endogenous catalase, glutathione peroxidase, and manganese SOD activities.
Furthermore, eff ects of naloxone on the somatosensory-evoked potentials (SEP) were studied in cat brains during focal cerebral ischemia by Ding et al.⁴² Th ey found that naloxone can improve the electrical activity of neurons in the ischemic region of the brain. Gunnarsson et al.⁴³ have shown that naloxone stereospecifi cally enhanced the SEP without changes in cortical blood fl ow. Th e high dose of naloxone needed to enhance the SEP suggested that the attenuation was mediated by low-affi nity opioid receptors (δ or κ). Th e same model was used to study the eff ect of naloxone-methobromide, a quaternary derivative of naloxone with selective peripheral action when injected intravenously. Only naloxone changed the amplitude of SEP signifi cantly compared to the control. However, there was a tendency for a delayed eff ect of naloxone-methobromide on SEP, possibly indicating that the substance slowly passed the blood-brain barrier.
Naloxone is Protective in SCI
Studies have shown that naloxone infl uences the pathophysiology of SCI.⁴⁴ Naloxone has been subjected to rigorous testing to determine its ability to protect compromised but viable cellular elements and improve the functional outcome of survivors, thus potentially serving as a useful agent for this purpose.⁴⁵ Kunihara et al.⁴⁶ studied the eff ect of naloxone on EAAs in cerebrospinal fl uid (CSF) in patients undergoing thoracoabdominal aortic surgery. In patients with SCI, CSF levels of glutamate and glycine continued to increase for as long as 72 hours postoperatively, and were signifi cantly more elevated than those without SCI. Postoperative maximum levels of CSF glutamate and glycine were also signifi cantly higher in patients with postoperative SCI than those without SCI. Naloxone signifi cantly decreased the CSF levels of glutamate and aspartate and the postoperative maximum level of CSF aspartate.⁴⁶ Th e eff ects of naloxone on behavioral recovery following unilateral peripheral vestibular deaff erentation (unilateral labyrinthectomy, UL) in guinea pigs was fi rst investigated by Dutia et al.⁴⁷ Naloxone was found to signifi cantly reduce the frequency of spontaneous nystagmus relative to controls, suggesting that naloxone can reduce the oculomotor eff ects of UL in a dose-dependent fashion. Th e infl uence of naloxone on spinal cord conduction and edema formation after trauma, measured by spinal cord evoked potentials (SCEP) and water content of the cord, respectively, was investigated in a rat model.⁴⁸ Pretreatment with naloxone inhibited the immediate postinjury decrease of the rostral maximal negative peak (MNP) amplitude without any signifi cant eff ect on latency changes. Measurement of water content in the traumatized spinal cord segment showed a signifi cant reduction by naloxone compared to controls.
IV. INFLAMMATION-MEDIATED NEURODEGENERATIVE DISEASES
Increasing evidence indicates that infl ammation plays a pivotal role in numerous neurodegenerative disorders, such as Parkinson's disease (PD),⁴⁹-⁵¹ Alzheimer's disease (AD),⁵² multiple sclerosis (MS),⁵³,⁵⁴ stroke,⁵⁵-⁶¹ prion disease,⁶²-⁶⁷ HIV dementia,⁶⁸-⁷³ Pick's disease,⁷⁴,⁷⁵ demyelination,⁷⁶,⁷⁷ and Guillain-Barré syndrome (GBS).⁷⁸ Th e pathology and clinical manifestations of neurodegenerative diseases often develop over years, indicating a progressive process. Th is gradual accumulation of damage across time suggests a large potential treatment window, off ering a therapeutic hope to alter the disease course. While there are few treatment approaches professing to slow the progression of neurodegenerative disease, current research suggests that anti-infl ammatory drugs can slow or even halt the propagation of neuronal death.⁷⁹-⁸¹ Here, we introduce morphinans as an ideal class of neuroprotective compounds that attenuate the infl ammation linked to the ongoing vicious cycle of neurodegeneration and that possess multiple neuroprotective characteristics.
Traditionally, the central nervous system (CNS) was perceived as an immunologically privileged structure devoid of immune cell infl uence. Current evidence indicates that the CNS is under constant immune surveillance in both normal physiological conditions and pathological circumstances. Studies of both humans and animals reveal that neuro-infl ammation participates in the pathogenesis and progression of numerous neurological diseases.⁸²-⁹¹ PD is an age-related chronic and ultimately devastating neurodegenerative disorder in the CNS characterized by a selective, progressive, and massive loss of dopamine (DA) neurons in the substantia nigra pars compacta (SNpc) and subsequent deple-tion of the neurotransmitter DA in the striatum, which leads to major clinical and pathological abnormalities.⁹²,⁹³ To date, both the cause and the detailed mechanism of DA neuron death in PD are unknown.
Research by McGeer et al.⁸³ was the fi rst to suggest roles of neuro-infl ammation in the pathogenesis of PD. In their report, a large population of reactive microglia, the resident phagocyte in the brain, staining positive for the human leukocyte antigen (HLA)-DR, was discovered in the substantia nigra (SN) of PD patients. In another study, the premise of an immunological response in PD was further supported by analysis of postmortem brains from PD patients, where there was clear evidence of microglia activation in the SN.⁹³ Several pro-infl ammatory cytokines have been detected in postmortem brains of PD patients, and there is evidence of oxidative stress, which also lends strong support to the association of microglial activation and PD.⁹³,⁹⁴ Furthermore, cases of immunological insults to the brain have recently been linked to the onset of PD.⁵¹ Specifi cally, reports have correlated early-life brain injury, fetal brain infl ammation, and viruses or infectious reagents with the later onset of PD.⁵⁰ Th us, in addition to the massive loss of DA neurons in the SNpc, PD is also characterized by a conspicuous (localized) glial overactivation, which is evidenced by elevated levels of cytokines and upregulation of infl ammation-associated factors, such as cyclooxygenase-2 (COX-2) and inducible nitric oxide synthases (iNOS).
V. ROLE OF MICROGLIA IN INFLAMMATION-MEDIATED NEURODEGENERATION
Increasing evidence supports microglia as the pivotal cell type mediating neuro-infl ammatory damage.⁹⁵-¹⁰⁸ Microglia are derived from the myeloid cell lineage, thus possessing many characteristics required for the innate immune response. Microglia engage in phagocytic functions to remove damaged and foreign cells and are further involved in immunological surveillance by secreting pro-infl ammatory factors, such as prostaglandins, tumor necrosis factor α (TNFα), interleukin-1 (IL-1), and free radicals, such as superoxide and nitric oxide (NO). Recent work in our laboratory has shown that much of the microglia-mediated neurotoxicity is through the release of superoxide and other reactive oxygen species (ROS) generated from nicotinamide adenine dinucleotide phosphate (NADPH) oxidase.⁸⁷,¹⁰⁹-¹¹⁴ Microglia serve the role of immune surveillance under normal physiological condition.⁸⁶ However, in pathological circumstances, microglia easily become activated and produce an array of neurotoxic factors, including cytokines and ROS. It is the overactivated microglia that govern the disease state, where the consequent accumulation of neurotoxic factors is deleterious to neurons. In PD, DA neurons in the SNpc are especially vulnerable to oxidative damage because of their reduced antioxidant capacity and potential defect in mitochondrial function.¹¹⁵ Because the SN is particularly rich in microglia,⁹⁰,¹¹⁶ the activation of microglia and subsequent release of neurotoxic factors contribute to DA neurodegeneration associated with PD.
Even without a direct immune trigger (such as LPS) stimulating the pro-infl ammatory response required for the DA neuronal death, microglia activation is also implicated in the case of DA neuronal death caused directly by neurotoxins, such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Specifically, the initial death of the neuron itself serves as a potent immunological stimulus, resulting in slow and persistent microglia activation, so called "reactive microgliosis."¹¹⁵ Because the presence of neurons inhibits the microglia-induced infl ammatory response, the death of neurons not only activates microglia, but also removes some of the anti-infl ammatory factors essential for maintaining microglial infl ammatory homeostasis.¹¹⁷ Regardless of the trigger, once passing the stimulus threshold, microglia can enter a selfpropelling cycle of infl ammation, resulting in slow and persistent neuronal death, commonly referred to as reactive microgliosis. Th us, microglia are fundamental to the progression of DA neurodegeneration as both a potential trigger for neurotoxicity and the engine driving the immunotoxic neuronal death resulting from reactive microgliosis.
In addition to the individual contributions to the neurotoxicity, a variety of factors probably work in concert to cause the synergistic DA neurotoxicity, which is particularly relevant to the complex neuroinfl ammatory mechanisms of the in vivo PD process. For example, NO and superoxide can interact with each other and form more toxic intermediates such as peroxynitrite.⁵¹
VI. CURRENT THERAPEUTIC STRATEGIES FOR NEURODEGENERATIVE DISORDERS
Traditional anti-infl ammatory drugs have also been studied for years for their possible therapeutic utility against neurodegenerative disorders. Dexamethasone is a steroidal anti-infl ammatory drug (SAID) shown to inhibit microglial activation and reported to alleviate the neurodegenerative process induced by lipopolysaccharide (LPS).¹¹⁸ However, it will be not clinically useful for long-term therapy because of its severe side eff ects.
Nonsteroidal anti-infl ammatory drugs (NSAIDs) have also been studied for their potential therapeutic eff ect on PD.¹¹⁹ Much epidemiological and limited clinical evidence suggests that NSAIDs can impede the onset and slow the progression of neurodegenerative diseases. However, these drugs strike only at the periphery of the infl ammatory reaction.⁵² Specifi cally, eff ects of NSAIDs on the CNS consist of a partial and limited spectrum of action on selective neurotoxic factors. For example, COX-2 inhibitors emerged as a novel agent for attenuating MPP + -elicited depletion of DA in the striatum and MPTP-induced loss of DA neurons in the SNpc.
However, other results raise concerns about the mechanism of NSAIDs' action. For example, corticosterone and aspirin only partially block the infl ammatory factors (prostaglandin E₂ [PGE₂], TNFα, NO) and represent an unsuccessful therapeutic approach for neurodegenerative diseases. Hence, much better results might be obtained if drugs were identifi ed that could inhibit the microglial activation or the production of an array of proinfl ammatory and neurotoxic factors in the brain, or if combinations of drugs were aimed at diff erent infl ammatory targets as eff ective therapy.
Anti-infl ammatory drugs designed to attenuate microglial activation hold the promise of a two-fold therapeutic benefi t. Fırst, there is the possibility of blocking the initial immunological insult that triggers the infl ammatory cascade event resulting in neuronal death. Second, there is the promise of further neuroprotection by slowing down or halting the perpetuated and self-propelling reactive microgliosis, regardless of the initial neurotoxic event.
Morphinans are a series of compounds structurally similar to morphine (Fıg. 1) but lacking the E ring found in the naturally occurring opioids, as well as the 6-OH and the 7,8-double bond. Th is work proposes that morphinan compounds, including naloxone, DM (3-methoxy-17-methylmorphinan), and its analog 3-HM (Fıg. 1) are innovative and neuroprotective agents for infl ammation-related neurological disorders through inhibition of microglial activationmediated neurotoxicity.
VII. NALOXONE IS NEUROPROTECTIVE
Endogenous opioid peptides are reported to exert their physiological eff ects through interaction with their respective opioid receptors. Th ese peptides are important in regulating the development of neurons and in modulating a variety of cellular activities, such as the immune response, respiration, ion channel action, and nociceptive/analgesic eff ects.¹²⁰ Naloxone is a potent nonselective antagonist of the classic Gprotein-linked opioid receptors, which are widely expressed on the cells in the CNS and peripheral nervous system. Naloxone has a similar affi nity for the µ-type opioid receptor, as does morphine.¹²¹ Th e capacity of naloxone as an opiate receptor antagonist is stereospecifi c: only (-)-naloxone is eff ective, while the (+)-enantiomer is considered inert at opioid receptors.¹²²,¹²³ Infl ammation-mediated DA neurodegeneration in the rat SN and in primary mesencephalic mixed neuronglia cultures resulting from the targeted injection and treatment with LPS have been serving as widely accepted and useful in vivo and in vitro models, respectively. Th ese models can be used to gain further insight into the pathogenesis and therapy of PD.
Microglia, the fi rst line of defense in the brain, produce free radicals such as superoxide, contributing to neurodegeneration. Chang et al.¹²⁴ studied the eff ects of naloxone on the production of superoxide from the murine microglial cell line, BV2, stimulated with LPS as measured by electron paramagnetic resonance (EPR). Th e production of superoxide triggered by phobol-12-myristate-13-acetate (PMA) resulted in SOD-inhibitable, catalase-uninhibitable 5,5-dimethyl-1-pyrroline N-oxide (DMPO) hydroxyl radical adduct formation. LPS enhanced the production of superoxide and triggered the formation of the non-heme iron/nitrosyl complex. Cells pretreated with naloxone showed signifi cant reduction of superoxide production by 35%. However, the relationship between the neuroprotective eff ects of naloxone and microglial activation was not elucidated in this study.
Recent work from our laboratory demonstrated that naloxone holds promise as a neuroprotective agent through the inhibition of neuro-infl ammation characterized by microglial activation.¹²⁰,¹²⁵ Treatment of rat mesencephalic mixed neuron-glia cultures with LPS activated microglia to release proinfl ammatory and neurotoxic factors (TNFα, NO, IL-1β, and superoxide), which subsequently caused damage to midbrain DA neurons. Th e LPS-induced DA neurodegeneration was signifi cantly reduced by naloxone (Fıg. 2). Th e underlying mechanism for this protective eff ect of naloxone on DA neurons was shown to be related to the inhibition of the activation of microglia (Fıg. 3) and their release of NO, TNFα, and IL-1β, and most importantly superoxide free radical (Fıg. 4). Both naloxone and its opioid receptor inactive stereoisomer (+)-naloxone protected DA neurons with equal potency (Fıg. 2) . Th ese results demonstrate that the underlying mechanism(s) of the neuroprotective eff ect of naloxone may be closely related to its ability to interfere with activation of microglia and their production of pro-infl ammatory and neurotoxic factors and that inhibition of microglial generation of superoxide free radical best correlates with the neuroprotective eff ect of naloxone isomers.¹²⁰ In the in vivo model of infl ammation-mediated neurodegeneration, injection of LPS via an osmotic minipump into the rat SN led to the activation of microglia and degeneration of DA neurons: microglial activation was observed at as early as 6 hours, and loss of DA neurons was detected 3 days after LPS injection.¹²⁶ Furthermore, the LPS-induced loss of DA neurons in the SN was time-and LPS concentration-dependent. Systemic infusion of either (-)-naloxone or (+)-naloxone inhibited the LPS-induced activation of microglia and signifi cantly reduced the LPS-induced loss of DA neurons in the SN (Fıg. 5). Th ese in vivo results, combined with previous observations in the mesencephalic neuron-glia cultures, confi rmed that naloxone protected DA neurons against infl ammation-mediated degeneration through inhibition of microglial activation and their release of pro-infl ammatory and cytotoxic factors (NO, TNFα, IL-1β, and most importantly superoxide free radical).¹²⁵ Th us, these studies demonstrate that both stereoisomers of naloxone attenuate the infl ammation-mediated DA neurodegeneration in an opioid receptor-independent manner by inhibiting microglial activation both in vivo¹²⁰ and in vitro.¹²⁵ To determine whether naloxone exerts neuroprotective eff ects beyond LPS models of neurotoxicity, we have also used the other models of neurotoxin-induced neurodegeneration. For this purpose, we have determined the protective eff ect of naloxone and its isomers on Aβ (1-42)-induced neurodegeneration.¹²⁷ Pretreatment of either cortical or mesencephalic neuron-glia cultures with 1-10 µM (-)-naloxone prior to treatment with 0.1-3 µM Aβ (1-42) aff orded signifi cant neuroprotection, as judged by DA uptake (Fıg. 6), immunocytochemical analysis, and cell counting. More importantly, (+)-naloxone, the ineff ective enantiomer of (-)-naloxone in binding opioid receptors, was equally eff ective in aff ording neuroprotection. Mechanistically, inhibition of Aβ (1-42)-induced superoxide production from microglia underlay the neuroprotective eff ect of naloxone stereoisomers (Fıg. 7). Moreover, a neuroprotective eff ect comparable to that of naloxone and inhibition of Aβ (1-42)-induced superoxide production was also achieved with naloxone methiodide, a charged analog with quaternary amine, suggesting that the site of action for naloxone isomers is at the cell surface of microglia. However, the specifi c site of action for naloxone on microglia remains undescribed.¹²⁷ Th ese results demonstrated that naloxone isomers, through mechanisms independent of the traditional opiate receptors, were capable of inhibiting Aβ (1-42)-induced microglial activation and degeneration of both cortical and mesencephalic neurons. Combined with our previous fi ndings with infl ammagen-induced neurodegeneration, naloxone analogs, especially (+)-naloxone, may have potential therapeutic effi cacy for the treatment of both PD and AD. Th us, the seeming lack of selectivity in its neuroprotective eff ect may actually suggest a broader spectrum of effi cacy in combating various infl ammation-related neurodegenerative disorders.
VII.C. Femtomolar Concentrations of Naloxone Are Neuroprotective
We have previously reported that femtomolar concentrations of the opiate peptide dynorphin,¹-¹⁷ a κ−receptor agonist, protect mesencephalic DA neurons from microglia-mediated neurotoxicity through a mechanism that was independent of the traditional opiate receptors.¹²⁸ Th is opiate peptide can be reduced to the smallest biologically active fragment required for DA neuroprotection, glycine-glycine-phenylalanine (GGF). Qin et al.¹³² found that GGF and naloxone at femtomolar concentrations showed similar dose response and effi cacy when these compounds were compared for their ability to inhibit microglial activation and confer DA neuroprotection from LPS in vitro (Fıg. 8). Furthermore, femtomolar concentrations of both GGF and naloxone were shown to attenuate microglial response to LPS by inhibition of NADPH oxidase activation. While GGF is a component of dynorphin, which binds to the κ receptor, GGF peptide fragment is unable to bind the κ−receptor. Naloxone, a nonspecifi c opiate antagonist, is also neuroprotective at femtomolar concentrations, indicating a femtomolar-acting mechanism independent of the traditional opiate receptor. Pharmacophore analysis of dynorphin peptides and naloxone revealed common chemical properties (hydrogen bond acceptor group, hydrogen bond donor group, positive ionizable group, and hydrophobic group) of these femtomolar-acting compounds. Th ese results support that GGF and naloxone share similar effects, common chemical properties, and mechanisms at femtomolar doses, suggesting that naloxone is a femtomolar mimetic for dynorphin, independent of the traditional opiate receptor.
NADPH oxidase is involved in the neuroprotective action of naloxone at both micromolar and femtomolar concentrations; however, the detailed mechanism is not yet clear. We speculate that both micromolar and femtomolar concentrations of naloxone and GGF inhibit the enzyme activity of NADPH oxidase by binding to the diff erent sites of action on the gp91 subunit. Research is ongoing in our lab to test this hypothesis.
VII.D. Naloxone Protects Against Brain Ischemia
Th e pathogenesis of cerebral I/R involves cytokine/ chemokine production, infl ammatory cell infl ux, astrogliosis, cytoskeletal protein degradation, and breakdown of the blood-brain barrier.⁴¹ (-)-Naloxone is able to reduce infarct volume and has been used as a therapeutic agent for cerebral I/R injuries. After cerebral I/R, the neuronal damage was strongly associated with gliosis, infl ammatory cell infi ltration, cytokine/chemokine overproduction, and matrix metalloproteinase-9 activation. (-)-Naloxone pretreatment suppresses post-ischemia-induced infl ammation and neuronal damage. Th erefore, (-)-naloxone administration might be an eff ective therapeutic intervention for reducing ischemic injuries in which the anti-infl ammatory mechanism may be involved.⁴¹
VIII. DM IS NEUROPROTECTIVE
Based on our fi ndings that naloxone had signifi cant neuroprotective eff ect on DA neurons mediated through a non-opioid receptor mechanism, we speculated that another morphinan compound DM, which shares the basic morphine-like structure with naloxone, might also show neuroprotective eff ect in a NMDA receptor-independent fashion. Th us, studies were conducted to test this hypothesis, and we found that DM and its analogs are protective of the DA neurons against infl ammation-related neurodegeneration through a mechanism similar to that of naloxone. 
VIII.A. DM Protects Against LPS-Induced DA Neurodegeneration In Vitro
Fırst, we have reported that DM protected DA neurons against infl ammation-mediated degeneration.¹²⁹ Our novel fi nding was that 1-10 µM DM protected DA neurons against LPS (10 ng/mL)-induced reduction of DA uptake functionally in rat primary mixed mesencephalic neuron-glia cultures (Fıg. 9). DM (10 µM) signifi cantly attenuated the LPS-induced reduction in the number of DA neurons (Fıg. 9). Morphologically, in LPS-treated cultures, in addition to the reduction of abundance of DA neurons, the dendrites of the remaining DA neurons were signifi cantly less elaborate than those of controls. In cultures pretreated with DM (10 µM) before LPS stimulation, DA neurons were signifi cantly more numerous and the dendrites less aff ected. Signifi cant neuroprotection was observed in cultures with DM added up to 60 minutes after the addition of LPS. Th us, DM signifi cantly protects DA neurons not only with pretreatment but also with post-treatment. It is well known that 1-methyl-4-phenylpyridinium (MPP + ), the active component of MPTP, damages DA neurons directly. Pretreatment of neuron-enriched cultures with DM (10 µM) did not signifi cantly alter the magnitude of the MPP + -induced reduction of DA uptake, suggesting that the neuroprotective eff ect of DM was mediated through microglia.
Activated microglia secrete a variety of pro-infl ammatory and neurotoxic factors, including ROS and cytokines. We found that DM dose-dependently decreased the production of superoxide, NO and TNFα either in neuron-glia or microglia-enriched cultures after LPS treatment. So the neuroprotective eff ect of DM on DA neurons did not appear to involve NMDA receptors, but rather directly related to its ability to inhibit the microglial activation with the release of superoxide, NO and TNFα, among which inhibition of superoxide production by DM was most pronounced (Fıg. 10).
Th e mechanism of the neuroprotective eff ect of DM in this PD model is associated with the inhibition of microglial activation but not with its NMDA receptor antagonist property. We have examined several NMDA receptor antagonists, including MK801, AP5, and memantine, in the LPS in vitro PD model (unpublished observations). Results from these studies indicate that among these compounds tested there was no correlation between the affi nity of NMDA receptor antagonist activity and the potency of the neuroprotection on DA neurons. On the contrary, a better correlation was found between the anti-infl ammatory potency and the neuroprotection. Th ese results suggest that the DA neuroprotection provided by DM in the infl ammation-related neurodegenerative models is not mediated through the NMDA receptor. Th is conclusion is not in confl ict with the previous reports, indicating that NMDA receptor blockade is associated with the neuroprotecive eff ect of DM in acute glutamate-induced excitotoxicity models. 
VIII.B. DM Protects DA Neurons from MPTP-Induced Damage Through Inhibition of Reactive Microgliosis
Recent animal studies from our laboratory revealed that DM also exerted potent protection for DA neurons in the subchronic MPTP mice model, in which the underlying mechanisms for neuroprotective activity of DM were also investigated using wild-type and NADPH oxidase-defi cient mice.¹⁰⁹ We fi rst found that C57 wild-type mice that received daily MPTP (15 mg free base/kg body weight s.c.) injections exhibited signifi cant loss of DA neurons in the SNpc. However, the MPTP-elicited neuronal loss was signifi cantly attenuated in those mice receiving daily injections of DM (10 mg/kg body weight).
NADPH oxidase is the primary enzyme producing extracellular superoxide in microglia, and we speculate that NADPH oxidase may contribute to MPTP-induced neurotoxicity.⁸⁷,¹⁰⁹-¹¹⁴ We found that NADPH oxidase-defi cient mice exhibited signifi cant resistance to MPTP-induced DA neuro degeneration compared to wild-type mice. In addition, the neuroprotective eff ect of DM was only observed in wildtype mice, but not in NADPH oxidase-defi cient mice (Fıg. 11). Th ese results provide strong evidence injections. Six days after the last MPTP injection, mice were sacrifi ced and brain sections were stained for TH-ir neurons.
Eight mice were used for each group. The differences were analyzed using a multi-factorial ANOVA; a difference of indicating that NADPH-oxidase is a critical target mediating DM's neuroprotective activity in the MPTP in vivo model. We have reported that the reactive microgliosis is associated with the MPTP-induced DA neurodegeneration,¹¹² and we further propose that the inhibition of reactive microgliosis underlie the neuroprotective eff ect against MPTP toxicity by DM. Th e initial damage of dead neurons elicited by MPTP induces reactive microgliosis, which in turn activates NADPH oxidase through the translocation of cytosolic subunits to the cell membrane and generation of superoxide in wild-type mice. Th e neuroprotective eff ect of DM is attributed to its blockade of reactive microgliosis induced by DA neuronal death through the inhibition of both extracellular superoxide and intracellular reactive oxygen species (iROS). However, in NADPH-defi cient mice, reactive microgliosis fails to occur because of the lack of gp91 membrane-binding subunit, and hence DM can not exert its neuroprotective action (Fıg. 12).
Femtomolar Concentrations of DM are Neuroprotective
Similar to naloxone, femtomolar concentrations of DM also signifi cantly decreased LPS-induced production of NO, TNFα, PGE₂, and superoxide free radicals in primary microglia-enriched and mesencephalic neuron-glia cultures. Th e important role of superoxide in this ultra-low-concentration phenomenon was further demonstrated through DM's failure to show a neuroprotective eff ect in neuron-glia cultures from NADPH oxidase-defi cient mice. Th ese results reveal that the protective action of femtomolar concentrations of DM is also glia mediated and that inhibition of the production of superoxide plays a pivotal role in the neuroprotective action of DM. In addition, the mechanism of DM in reducing NO and PGE₂ is through inhibition of activity of iNOS and COX2 (Guorong Li et al.¹³³). Similar to the initial fi ndings reported with femtomolar concentrations of naloxone, DM is also likely a femtomolar-acting GGF mimetic.
VIII.D. 3-HM Is Neurotrophic to DA Neurons and Neuroprotective Against LPS-Induced Neurotoxicity
In order to fi nd more potent neuroprotective agents, structure-activity studies were performed. After screening a series of DM analogs, 3-HM, a DM analog missing methyl groups at the O and N sites, emerged as a novel candidate for the treatment of PD. Our study showed that 3-HM was more potent in neuroprotection against LPS-induced neurotoxicity than its parent compound, DM.¹³⁰ 3-HM was fi rst found to be neuroprotective against LPS-induced DA neurotoxicity and was also neurotrophic to DA neurons in primary mixed mesencephalic neuron-glia cultures (Fıg. 13).¹³⁰ Th e neurotrophic eff ect of 3-HM was glia dependent, in that 3-HM failed to show any protective eff ect in neuron-enriched cultures. We subsequently demonstrated that it was the astroglia and not the microglia that contributed to the neurotrophic eff ect of 3-HM. Th is conclusion was based on the reconstitution studies, in which we added diff erent percentages of microglia (10-20%) or astroglia (40-50%) back to the neuron-enriched cultures and found that 3-HM was neurotrophic after the addition of astroglia, but not microglia.
Furthermore, 3-HM-treated astroglia-derived conditioned media exerted a signifi cant neurotrophic eff ect on DA neurons (Fıg. 14). It appeared likely that 3-HM caused the release of certain neurotrophic factor(s) from astroglia, which in turn was responsible for the neurotrophic eff ect of 3-HM. As may be expected, there is also a considerable glial reaction in the SNpc in PD that can potentially be protective in addition to the detrimental eff ect on DA neurons. Glial cells, especially astroglia, protect stressed DA neurons through production of neurotrophic factor(s) that counteract oxidative stress. One potential therapeutic avenue will be to stimulate astroglia to produce these neurotrophic factors to rescue damaged or dying neurons. Currently, the identity of the neurotrophic factor(s) released from astroglia induced by 3-HM is being undertaken. of NADPH oxidase to the cell membrane and binds to the gp91 catalytic subunit, resulting in production of superoxide. The neuroprotective action of DM is attributed to its effective blockade of the reactive microgliosis induced by DA neuronal death through inhibiting the production of superoxide. In contrast, reactive microgliosis fails to induce the production of superoxide in NADPH-defi cient mice because of the lack of the gp91 catalytic subunit.
DM fails to show the neuroprotective effect as a result of the loss of its active binding site.
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In addition to the neurotrophic eff ect, the antiinfl ammatory mechanism was also important for the neuroprotective activity of 3-HM because the more microglia that were added back to neuron-enriched cultures, the more pronounced the LPS-induced neurotoxicity and the more signifi cant the neuroprotective eff ect exerted by 3-HM. Th e anti-infl ammatory mechanism of 3-HM was attributed to its inhibition of LPS-induced production of an array of pro-infl ammatory and neurotoxic factors, including NO, TNFα, PGE₂, and ROS.
Th us, 3-HM provides potent neuroprotection by acting on two diff erent cell targets: a neurotrophic eff ect mediated by astroglia and an anti-infl ammatory eff ect mediated by inhibition of microglial activation. Th e higher potency of 3-HM is attributed to its additional neurotrophic eff ect in addition to the anti-infl ammatory mechanism shared by both DM and 3-HM (Fıg. 15).
3-HM Protects DA Neurons Against MPTPElicited Degeneration In Vivo and In Vitro
To continue this line of research, we investigated the neuroprotective property of 3-HM in another PD model. We found that 3-HM provided neuroprotection in the MPTP model, in both in vivo and in vitro studies. In the in vitro system, using primary mixed mesencephalic neuron-glia cultures, 1-5 µM 3-HM signifi cantly and dose-dependently attenuated MPTP-induced, or its active component MPP + -induced, reduction in DA uptake; 1-5 µM 3-HM alone resulted in a signifi cantly high capacity of DA uptake compared with controls, confi rming its neurotrophic eff ect.
In vivo studies showed that administration of 3-HM (5 mg/kg body weight, s.c., twice daily) signifi cantly reduced MPTP (15 mg free base/kg body weight, s.c., once daily)-induced loss of DA neurons in the SNpc, which is similar to the eff ect exerted by DM. In the striatum, signifi cant depletion of DA and its metabolites 3,4-dihydroxyphenylacetic acid and promote the survival of DA neurons after LPS challenge; second is an anti-infl ammatory activity mediated by the inhibition of microglial activation and its subsequent generation of a variety of pro-infl ammatory and neurotoxic factors, including superoxide, iROS, NO, TNFα, and PGE2. Both the neurotrophic and anti-infl ammatory effects will prevent the vicious cycle, which occurs with the participation of microglial activation, release of pro-infl ammatory factors, the death of DA neurons, and reactive microgliosis.
(DOPAC) and homovanillic acid (HVA), as well as serotonin and its metabolite 5-hydroxyindolacetic acid (5-HIAA), were observed in MPTP-treated mice compared with controls. Th e levels of all of these biogenic amines were attenuated in the lesioned mice that received 3-HM administration (Fıg. 16).
Compared to DM, the advantage of 3-HM is the neurotrophic eff ect, which may enhance the sprouting of DA terminal fi bers of the striatum, accelerate the formation of DA-containing vesicles, assist the resynthesis of DA after the lesion, and eventually reestablish the return of DA to normal function. In addition to the neurotrophic eff ect, the antiinfl ammatory eff ect exerted by 3-HM resulting from the inhibition of microgliosis generated from the damaged DA neurons induced by MPTP/MPP + is another important mechanism of 3-HM. We have found that 3-HM inhibited the reactive microgliosis in primary mesencephalic neuron-glia cultures after MPTP/MPP + treatment (unpublished observations). ary microglial activation (reactive microgliosis), which is characterized by the production of superoxide and iROS, producing further DA neuronal death (self-propelling process). The dual actions are benefi cial both in reducing DA neuronal degeneration in the SNpc and in restoring the depletion of biogenic amines, including DA and its metabolites DOPAC and HVA, and serotonin and its metabolite 5-HIAA, thus providing a complete neuroprotection on the entire nigrostriatal pathway.
Th us, administration of 3-HM in MPTP in vivo and in vitro PD models is benefi cial both in reducing DA neuronal degeneration in the SNpc and restoring the depletion of biogenic amines in the striatum through dual functions of neurotrophic eff ect and reduction of reactive microgliosis, thus providing signifi cant neuroprotection (Fıg. 17).
In contrast to our fi nding that DM exerted neuroprotection through the inhibition of microglial overactivation, other studies supported a possible neurotrophic mechanism of DM. Vaglini et al.¹³¹ reported that DM prevented the diethyldithiocarbamate (DDC) enhancement of MPTP toxicity in mice. From a histological analysis, they found that the depletion of DA neurons induced by the combined DDC + MPTP treatment was completely prevented by DM. DM was also eff ective in preventing the toxicity of glutamate in mesencephalic cell cultures, evaluated via the [³H] DA uptake. DM showed the same pattern of protection as nicotine and MK801, which increased the fi broblastic growth factor in the striatum, indicating that DM might function through the same mechanism of neurotrophic action.
IX. CONCLUDING REMARKS
Neuro-infl ammation is critical for the pathogenesis of an array of neurodegenerative disorders. Anti-infl ammation therapy thus may be an eff ective strategy to slow down or even halt the progression of the neurodegeneration. In this review, we present evidence that morphinan compounds, including naloxone, DM, and their analogs, off er potentially potent neuroprotection in multiple infl ammatory disease models both by exerting a neurotrophic eff ect and by inhibiting microglial activation associated with the production of a host of pro-infl ammatory and neurotoxic factors, including NO, TNFα, PGE 2 , extra-cellular superoxide, and iROS. Th us, morphinans may off er a new therapeutic direction as promising compounds for the treatment of neuro-infl ammatory diseases.
